Indian Pharma Giants Commit $19.1 Billion to US Expansion, Signalling a New Phase in Global Growth

Indian pharmaceutical companies have announced plans to invest more than $19.1 billion in the United States, marking one of the largest overseas expansion waves by India’s drug industry. The commitments were highlighted during the 2026 SelectUSA Investment Summit in Maryland, where Indian companies across sectors pledged a record $20.5 billion in investments in the US. Pharma accounts for the overwhelming share of that total, reflecting the sector’s growing ambition to move beyond exports and build deeper manufacturing, research and commercial capacity inside the American market.

The investment push is anchored by Sun Pharmaceutical Industries’ planned $11.75 billion acquisition of Organon & Co, a New Jersey-based global healthcare company. The deal, already announced by Sun Pharma and Organon, will see Organon shareholders receive $14 per share in cash, valuing the company at an enterprise value of $11.75 billion. Reuters described it as the largest overseas acquisition by an Indian pharmaceutical company, underlining how Indian drugmakers are now using global acquisitions to gain scale, brands, specialised portfolios and direct access to mature markets.

The list of participating Indian pharma companies includes some of the country’s biggest names: Aurobindo Pharma, Biocon Group, Cipla, Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, Granules India, Jubilant Group, Lupin, Sun Pharmaceutical Industries, Piramal Pharma and Zydus Lifesciences. Their proposed investments are expected to support new manufacturing facilities, expansion of existing networks, research and development centres and broader supply-chain capacity in the United States.

The development is important because the US remains the world’s most important pharmaceutical market and a major destination for Indian generics, biosimilars and specialty medicines. For decades, Indian companies built their US presence mainly through exports, FDA-approved manufacturing sites in India and generic drug filings. The new investment wave suggests a shift towards a more localised and resilient model, where Indian companies may manufacture, research, package and commercialise more products inside the US itself.

This shift comes at a time when the US is trying to strengthen domestic healthcare supply chains and reduce vulnerability in essential medicines. According to the reports, the Indian investments are expected to help expand the supply of essential medicines, address drug shortages and strengthen the resilience of the US healthcare supply chain. For Indian companies, the strategy also reduces overdependence on price-sensitive generic exports and opens a path into higher-value areas such as biosimilars, branded generics, women’s health, specialty therapies and advanced pharmaceutical manufacturing.

Sun Pharma’s Organon acquisition shows the direction clearly. Organon has a portfolio of more than 70 products across women’s health, general medicines and biosimilars, commercialised across about 140 countries. The combined company is expected to give Sun Pharma a much larger global platform, entry into biosimilars as a major player and a stronger presence in women’s health. Organon said the transaction could position Sun Pharma among the top 25 global pharmaceutical companies, with combined revenue of about $12.4 billion after successful completion.

The broader investment pledge also has a diplomatic and trade dimension. US Ambassador to India Sergio Gor linked the announcements to the goal of doubling India-US bilateral trade to $500 billion by 2030. The SelectUSA platform is designed to attract foreign direct investment into the United States, and India’s record commitment at the summit shows how corporate investment is becoming an increasingly important pillar of the India-US economic relationship.

For India, the message is equally significant. The country’s pharmaceutical industry has long been known as the “pharmacy of the world” because of its strength in affordable generic medicines and vaccines. But the new US investment wave shows that Indian pharma is no longer satisfied with being only a low-cost supplier. It is now trying to become a global owner of brands, manufacturing networks, intellectual property, specialty portfolios and advanced R&D platforms.

The move also reflects changing realities in global healthcare. Drug shortages, regulatory scrutiny, supply-chain disruptions, rising demand for complex generics and the growth of biosimilars are forcing pharmaceutical companies to rethink where and how they manufacture. Indian drugmakers that once relied heavily on cost advantages are now positioning themselves as strategic partners in global health security.

The $19.1 billion investment commitment could mark a turning point for Indian pharma. It can deepen India’s presence in the US market, create new jobs and facilities in America, strengthen supply resilience, and give Indian companies a stronger foothold in high-value therapeutic segments. More importantly, it signals the arrival of Indian pharma as a global capital-deploying force — not just exporting medicines to the world, but building the infrastructure to shape the future of healthcare in the world’s largest drug market.

---

References:

The Pharma Letter – Indian pharma majors commit $19 billion to US expansion
https://www.thepharmaletter.com/generics-news/indian-pharma-majors-commit-19-billion-to-us-expansion

U.S. Embassy in India – Factsheet: Indian Investments in the United States at the 2026 SelectUSA Investment Summit
https://in.usembassy.gov/factsheet-indian-investments-in-the-united-states-at-the-2026-selectusa-investment-summit/

The Indian Express – Indian companies pledge to invest record $20.5 billion in US; pharma in focus
https://indianexpress.com/article/business/indian-companies-pledge-to-invest-record-20-5-billion-in-us-pharma-in-focus-10676921/

The Financial Express – Indian pharma firms pledge to invest a record $19.1bn in US at SelectUSA Summit
https://www.financialexpress.com/business/news/indian-pharma-firms-pledge-to-invest-a-record-19-1bn-in-us-at-selectusa-summit/4233335/

Organon – Sun Pharma signs definitive agreement to acquire Organon
https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/

Reuters – Sun Pharma to buy US drugmaker Organon for $11.75 billion in India’s largest pharma deal
https://www.reuters.com/business/healthcare-pharmaceuticals/sun-pharma-acquire-organon-1175-bln-all-cash-deal-2026-04-27/

---